Trials / Approved For Marketing
Approved For MarketingNCT01632826
Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
A Multicenter, Single-Arm, Open-Label Treatment Use Protocol for Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
To provide pomalidomide access to relapsed/refractory multiple myeloma subjects with a likelihood of benefit from the pomalidomide treatment while the medication is not commercially available
Detailed description
Several clinical studies indicate that pomalidomide has activity in relapsed and refractory multiple myeloma with response rates ranging between 30% and 60% at pomalidomide doses at 2 mg/day and/or 4 mg/day.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pomalidomide | 4 mg daily for 21 days in a 28 day cycle until disease progression or other reasons for treatment discontinuation |
Timeline
- First posted
- 2012-07-03
- Last updated
- 2019-11-12
Locations
42 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01632826. Inclusion in this directory is not an endorsement.